Pembrolizumab: tested in a combination

521 studies: another drug in the study is under test too. Page 2 of 6. Open to participants first (187), then studies with results posted, then the rest; newest registration first within each.

• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2Report a problem
• Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLCRecruitingNCT06132698Phase 2Report a problem
• A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2Report a problem
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2Report a problem
• Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCCRecruitingNCT06100497Phase 2Report a problem
• Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)Not yet recruitingNCT06086288Phase 2Report a problem
• Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2Report a problem
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCRecruitingNCT06078384Phase 2Report a problem
• Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingNCT06041503Phase 2Report a problem
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4Report a problem
• Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNot yet recruitingNCT06028633Phase 2Report a problem
• Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous CellRecruitingNCT06006650Phase 2Report a problem
• Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingNCT06006013Phase 2Report a problem
• Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract CancersRecruitingNCT06001658Phase 2Report a problem
• 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCCRecruitingNCT05980702Phase 2Report a problem
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor ThrombusRecruitingNCT05969496Phase 2Report a problem
• Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma PatientsRecruitingNCT05961761Phase 2Report a problem
• Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasRecruitingNCT05956041Phase 2Report a problem
• Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal CancerNot yet recruitingNCT05909423Phase 2Report a problem
• Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyRecruitingNCT05903833Phase 2Report a problem
• Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2Report a problem
• First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2Report a problem
• Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2Report a problem
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingNCT05766371Phase 2Report a problem
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2Report a problem
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2Report a problem
• Intraperitoneal Immune Checkpoint Inhibitor for Malignant AscitesEnrolling by invitationNCT05745233Not applicableReport a problem
• Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingNCT05733715Early Phase 1Report a problem
• Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingNCT05679921Phase 2Report a problem
• Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2Report a problem
• Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05623319Phase 2Report a problem
• A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2Report a problem
• Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05595447Phase 2/3Report a problem
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell CancerRecruitingNCT05583708Phase 2Report a problem
• Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)RecruitingNCT05563558Phase 2Report a problem
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)RecruitingNCT05549297Phase 3Report a problem
• Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingNCT05493566Early Phase 1Report a problem
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2Report a problem
• Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic CancerRecruitingNCT05462496Phase 2Report a problem
• Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCCRecruitingNCT05446467Phase 2Report a problem
• A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's LymphomaRecruitingNCT05355051Phase 2Report a problem
• Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal CancerNot yet recruitingNCT05333809Phase 2Report a problem
• Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor ThrombusRecruitingNCT05319015Phase 2Report a problem
• Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingNCT05313243Phase 2Report a problem
• Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal CancerRecruitingNCT05305131Phase 2Report a problem
• A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)RecruitingNCT05286619Phase 2Report a problem
• Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.Not yet recruitingNCT05286320Phase 1/2Report a problem
• Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerRecruitingNCT05284539Phase 2Report a problem
• Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCCRecruitingNCT05272696Phase 2Report a problem
• De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy InductionRecruitingNCT05255302Phase 2/3Report a problem
• Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic CancerRecruitingNCT05218629Phase 2Report a problem
• Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruitingNCT05188508Phase 2Report a problem
• Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2Report a problem
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)RecruitingNCT05185739Phase 2Report a problem
• Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasRecruitingNCT05182164Phase 2Report a problem
• Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingNCT05180097Phase 2Report a problem
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingNCT05155033Phase 2Report a problem
• Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic CancerRecruitingNCT05132504Phase 2Report a problem
• Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain MetastasesRecruitingNCT05064280Phase 2Report a problem
• Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2Report a problem
• Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)RecruitingNCT05027633Phase 2Report a problem
• Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaRecruitingNCT04997837Phase 3Report a problem
• Pembrolizumab and Lenvatinib in Advanced Cervical CancerRecruitingNCT04865887Phase 2Report a problem
• Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)RecruitingNCT04807673Phase 3Report a problem
• Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingNCT04724018Phase 1/2Report a problem
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2Report a problem
• Merck IIT: RRP Pembro and LenvatinibRecruitingNCT04645602Phase 2Report a problem
• Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerRecruitingNCT04592211Phase 1/2Report a problem
• Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2Report a problem
• Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerRecruitingNCT04519151Phase 2Report a problem
• Study of Pembrolizumab With Bendamustine in Hodgkin LymphomaRecruitingNCT04510636Phase 2Report a problem
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2Report a problem
• Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersRecruitingNCT04295863Phase 1Report a problem
• Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBCRecruitingNCT04265872Early Phase 1Report a problem
• Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2Report a problem
• Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaRecruitingNCT04150640Phase 2Report a problem
• Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingNCT03842943Phase 2Report a problem
• Converting HR+ Breast Cancer Into an Individualized VaccineRecruitingNCT03804944Phase 2Report a problem
• Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsRecruitingNCT03755739Phase 2/3Report a problem
• Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingNCT03719105Early Phase 1Report a problem
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2Report a problem
• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3Report a problem
• Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without NephroureterectomyNot yet recruitingNCT03345134Phase 2Report a problem
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
• Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingNCT02896335Phase 2Report a problem
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2Report a problem
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast CancerTerminatedNCT05756166Phase 1/2Results postedReport a problem
• Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersCompletedNCT05379972Phase 2Results postedReport a problem
• Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerTerminatedNCT05353439Phase 1Results postedReport a problem
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminatedNCT05308901Phase 2Results postedReport a problem
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerTerminatedNCT05263492Phase 2Results postedReport a problem
• A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive, not recruitingNCT05203445Phase 2Results postedReport a problem
• Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results postedReport a problem
• Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesCompletedNCT04967417Phase 2Results postedReport a problem
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results postedReport a problem
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerActive, not recruitingNCT04929392Phase 2Results postedReport a problem
• MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland CancerActive, not recruitingNCT04895735Phase 2Results postedReport a problem
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results postedReport a problem
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyCompletedNCT04865289Phase 3Results postedReport a problem

← Pembrolizumab